multiple sclerosis
Neurology · 2006–2025
45decisions
20medicines
23carried consumer input
130individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ocrelizumab Treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). Ocrelizumab SC provides an alternative subcutaneous administration route to the… | Jul 2025 | Recommended with restriction | 14 individuals |
| ublituximab Treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. | May 2025 | Recommended with restriction | 1 individuals |
| natalizumab Treatment of clinically definite relapsing-remitting multiple sclerosis (RRMS) to delay the progression of physical disability and reduce the frequency of… | Mar 2025 | Recommended with restriction | none received |
| ofatumumab Treatment of relapsing remitting multiple sclerosis (RRMS) in adult patients with relapsing forms of multiple sclerosis to delay progression of physical… | Mar 2024 | Not recommended | input received MS Australia |
| fingolimod, ofatumumab, siponimod Amendment to PBS listings to allow nurse practitioners to initiate and continue treatment of fingolimod, ofatumumab, and siponimod in consultation with a… | Nov 2024 | Recommended | input received |
| natalizumab Treatment of clinically definite relapsing-remitting multiple sclerosis (RRMS) via subcutaneous injection (150 mg in 1 mL prefilled syringe formulation). | Mar 2023 | Recommended with restriction | 8 individuals |
| cladribine Treatment of relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical relapses and to delay the progression of physical disability. | Nov 2023 | Not recommended | none received |
| natalizumab Treatment of clinically definite relapsing-remitting multiple sclerosis. | Jul 2022 | Recommended | none received |
| diroximel fumarate Treatment of relapsing-remitting multiple sclerosis (RRMS) in patients diagnosed as clinically definite RRMS by MRI with at least two documented relapses… | Mar 2022 | Recommended with restriction | 6 individuals MS Australia |
| glatiramer acetate Treatment of multiple sclerosis. The submission requested listing a new form of 40 mg glatiramer acetate pre-filled pen under the same circumstances as the… | Mar 2022 | Recommended | 1 individuals MS Australia |
| glatiramer acetate Treatment of relapsing-remitting multiple sclerosis (RRMS), including reduction of relapse frequency and treatment of patients with a single clinical event… | Mar 2021 | Recommended | none received |
| ofatumumab Treatment of relapsing-remitting multiple sclerosis (RRMS) in patients with clinically definite diagnosis confirmed by MRI of brain and/or spinal cord, who… | Mar 2021 | Recommended with restriction | 4 individuals MS Australia |
| tetracosactide Treatment of hypsarrhythmia and/or infantile spasms, and acute exacerbations in patients with multiple sclerosis. | Mar 2021 | Deferred | none received |
| cladribine Treatment of relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical relapses and to delay the progression of physical disability. | Nov 2021 | Not recommended | 1 individuals |
| ozanimod Treatment of clinically definite relapsing-remitting multiple sclerosis (RRMS) in adult patients. | Sep 2020 | Recommended with restriction | input received MS Australia |
| siponimod Treatment of relapse-onset phenotypes of multiple sclerosis (RRMS and SPMS), including patients with EDSS 6.0/6.5. | Jul 2020 | Recommended with restriction | 2 individuals |
| nabiximols Adjunctive treatment of moderate to severe spasticity in patients with multiple sclerosis who have not adequately responded to oral anti-spasticity agents. | Mar 2020 | Not recommended | 4 individuals |
| fingolimod Treatment of relapsing-remitting multiple sclerosis (RRMS) in paediatric and adolescent patients weighing 40 kg or less. | Jul 2019 | Recommended with restriction | input received |
| dimethyl fumarate Treatment of patients with relapsing-remitting multiple sclerosis (RRMS). | Nov 2019 | Recommended with restriction | none received |
| cladribine Treatment of relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical relapses and to delay the progression of physical disability. | Jul 2018 | Recommended with restriction | 8 individuals |
| cladribine Treatment of relapsing remitting multiple sclerosis (RRMS) to reduce the frequency of clinical relapses and to delay the progression of physical disability. | Mar 2018 | Not recommended | 26 individuals |
| glatiramer acetate Treatment of clinically isolated syndrome suggestive of multiple sclerosis in patients thought to be at high risk of subsequent diagnosis with clinically… | Jul 2017 | Not recommended | input received |
| ocrelizumab Treatment of relapsing-remitting multiple sclerosis (RRMS) in adult patients. Ocrelizumab is positioned as a first-line alternative to fingolimod, natalizumab… | Jul 2017 | Recommended with restriction | 10 individuals |
| cladribine Treatment of relapsing-remitting multiple sclerosis (RRMS) to reduce the frequency of clinical relapses and to delay the progression of physical disability. | Nov 2017 | Not recommended | 5 individuals |
| daclizumab Treatment of relapsing-remitting multiple sclerosis (RRMS) in patients with clinically definite disease, at least 2 documented attacks in the preceding 2… | Jul 2016 | Deferred | input received |
| dimethyl fumarate Treatment of patients with relapsing-remitting multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability. | Jul 2016 | Recommended | input received |
| teriflunomide Treatment of patients with relapsing-remitting multiple sclerosis (RRMS). | Nov 2016 | Not recommended | none received |
| glatiramer acetate Initial and continuing treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory patients who have experienced at least two… | Mar 2015 | Recommended | input received |
| alemtuzumab Treatment of relapsing-remitting multiple sclerosis with active disease defined by clinical or imaging features. | Jul 2014 | Recommended with restriction | 40 individuals |
| fampridine Symptomatic improvement of walking ability in ambulatory patients with clinically definite multiple sclerosis who meet specified criteria (EDSS score 4-7,… | Mar 2014 | Not recommended | unclear |
| alemtuzumab Treatment of relapsing-remitting multiple sclerosis (RRMS), as first-line therapy in patients with poor prognostic signs and as escalation therapy in… | Nov 2014 | Not recommended | unclear |
| peginterferon beta-1a First-line treatment of patients with remitting-relapsing multiple sclerosis who have experienced at least 2 documented attacks of neurological dysfunction in… | Nov 2014 | Recommended with restriction | input received |
| dimethyl fumarate Treatment of relapsing-remitting multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability. | Jul 2013 | Recommended | no section in document |
| nabiximols Treatment of moderate to severe spasticity due to multiple sclerosis in patients who are intolerant to anti-spasticity medication and/or have not adequately… | Jul 2013 | Not recommended | unclear |
| teriflunomide Initial and continuing treatment of relapsing-remitting multiple sclerosis (RRMS) in ambulatory patients who have experienced at least 2 documented attacks of… | Jul 2013 | Recommended with restriction | unclear |
| fampridine Symptomatic improvement of walking ability in ambulatory patients with clinically definite multiple sclerosis. | Nov 2012 | Not recommended | unclear |
| teriflunomide Initial and continuing treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory patients who have experienced at least 2… | Nov 2012 | Not recommended | unclear |
| fampridine Symptomatic improvement of walking ability for an ambulatory patient with clinically definite multiple sclerosis who meets certain criteria. | 2012 | Not recommended | unclear |
| Teriflunomide Initial and continuing treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory patients who meet certain criteria. | 2012 | Recommended | unclear |
| cladribine initial and continuing treatment of relapsing–remitting multiple sclerosis (RRMS) in an ambulatory patient who has experienced at least two documented attacks… | Mar 2011 | Not recommended | no section in document |
| fingolimod Initial treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory (without assistance or support) patients who have experienced at… | Mar 2011 | Recommended | unclear |
| Interferon beta-1b treatment of ambulatory patients with relapsing-remitting multiple sclerosis (MS) characterised by at least two attacks of neurologic dysfunction over a two… | Mar 2007 | Not recommended | no section in document |
| interferon beta-1b Treatment of relapsing-remitting multiple sclerosis in ambulatory patients diagnosed using McDonald criteria, including those with a single clinical attack and… | Mar 2007 | Not recommended | no section in document |
| natalizumab initial and continuing treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory patients eighteen years of age or older. | Nov 2006 | Not recommended | no section in document |
| natalizumab Initial and continuing treatment of clinically definite relapsing-remitting multiple sclerosis in ambulatory patients eighteen years of age or older. | Nov 2006 | Recommended with restriction | no section in document |
Who spoke
MS Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 23 of 32 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.